{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+and+Metastatic+Solid+Tumors&page=9", "query": { "condition": "Locally Advanced and Metastatic Solid Tumors", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 405, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+and+Metastatic+Solid+Tumors&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+and+Metastatic+Solid+Tumors&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T14:15:16.962Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06667141", "title": "Study of ACR-2316 in Specific Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Specific Advanced Solid Tumors" ], "interventions": [ { "name": "ACR-2316", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acrivon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-10-08", "completion_date": "2027-12-12", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-21T14:15:16.962Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Newport Beach, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06667141" }, { "nct_id": "NCT03260322", "title": "A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ASP8374", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2017-09-08", "completion_date": "2022-05-10", "has_results": false, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-10-21T14:15:16.962Z", "location_count": 19, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03260322" }, { "nct_id": "NCT03428802", "title": "Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Locally Advanced Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "POLD1 Gene Mutation", "POLE Gene Mutation", "Recurrent Malignant Solid Neoplasm", "Recurrent Ovarian Carcinoma", "Stage III Breast Cancer AJCC v7", "Stage III Ovarian Cancer AJCC v8", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIC Breast Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2018-03-08", "completion_date": "2027-09-21", "has_results": true, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-21T14:15:16.962Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey • New York, New York", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03428802" }, { "nct_id": "NCT02174172", "title": "A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Interferon alfa-2b", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "PEG-interferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2014-08-18", "completion_date": "2019-11-25", "has_results": false, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-10-21T14:15:16.962Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02174172" }, { "nct_id": "NCT06616766", "title": "A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NSCLC (Non-small Cell Lung Cancer)", "Solid Tumor" ], "interventions": [ { "name": "YH42946", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yuhan Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 201, "start_date": "2024-10-02", "completion_date": "2028-07-29", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-21T14:15:16.962Z", "location_count": 1, "location_summary": "Fairfax, Virginia", "locations": [ { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06616766" }, { "nct_id": "NCT06299761", "title": "Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "BBI-825", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boundless Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 19, "start_date": "2024-03-28", "completion_date": "2025-06-25", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-10-21T14:15:16.962Z", "location_count": 5, "location_summary": "Santa Monica, California • Grand Rapids, Michigan • New York, New York + 2 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Irving", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06299761" }, { "nct_id": "NCT03868423", "title": "Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Neoplasm", "ALK Fusion Protein Expression", "ALK Gene Amplification", "ALK Gene Mutation", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Malignant Neoplasm in the Central Nervous System", "Metastatic Malignant Solid Neoplasm", "ROS1 Fusion Positive", "ROS1 Gene Amplification", "ROS1 Gene Mutation" ], "interventions": [ { "name": "Brigatinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sameek Roychowdhury", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-03-20", "completion_date": "2021-12-30", "has_results": false, "last_update_posted_date": "2022-02-18", "last_synced_at": "2026-10-21T14:15:16.962Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03868423" }, { "nct_id": "NCT06413680", "title": "A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Clear-Cell Renal-Cell Carcinoma (ccRCC)", "Advanced Solid Tumors" ], "interventions": [ { "name": "REGN10597", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2024-09-23", "completion_date": "2030-02-03", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-10-21T14:15:16.962Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • North Haven, Connecticut + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "North Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06413680" }, { "nct_id": "NCT04457778", "title": "First in Human Study of M6223", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumors" ], "interventions": [ { "name": "M6223", "type": "DRUG" }, { "name": "Bintrafusp alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2020-07-10", "completion_date": "2023-06-23", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-21T14:15:16.962Z", "location_count": 3, "location_summary": "Nashville, Tennessee • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04457778" }, { "nct_id": "NCT02610075", "title": "Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Solid Tumours", "Metastatic Solid Tumours", "Ovarian Cancer" ], "interventions": [ { "name": "AZD1775", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 62, "start_date": "2015-12-01", "completion_date": "2018-04-26", "has_results": false, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-10-21T14:15:16.962Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02610075" } ] }